- Home
- FDMT
as 07-26-2024 4:00pm EST
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | 927.6M | IPO Year: | 2020 |
| Target Price: | $46.25 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.44 - $36.25 | Next Earning Date: | 08-07-2024 |
| Revenue: | $20,452,000 | Revenue Growth: | 826.69% |
| Revenue Growth (this year): | -72.28% | Revenue Growth (next year): | 28.86% |
Stock Insider Trading Activity of 4D Molecular Therapeutics Inc. (FDMT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bizily Scott | FDMT | Chief Legal Officer | Jul 11 '24 | Sell | $25.00 | 1,996 | $49,900.00 | 6,781 | SEC Form 4 |
| Bizily Scott | FDMT | Chief Legal Officer | Jul 1 '24 | Sell | $21.36 | 4,248 | $90,757.67 | 1,737 | SEC Form 4 |
| Kirn David | FDMT | Chief Executive Officer | Jun 24 '24 | Sell | $23.10 | 12,930 | $298,711.45 | 1,059,153 | SEC Form 4 |
| Bizily Scott | FDMT | Chief Legal Officer | Jun 17 '24 | Sell | $23.71 | 1,750 | $41,493.55 | 1,737 | SEC Form 4 |
| Bizily Scott | FDMT | Chief Legal Officer | May 16 '24 | Sell | $25.34 | 1,283 | $32,513.79 | 2,204 | SEC Form 4 |
| Bizily Scott | FDMT | Chief Legal Officer | May 16 '24 | Sell | $25.75 | 467 | $12,027.26 | 1,737 | SEC Form 4 |
| Bizily Scott | FDMT | Chief Legal Officer | Apr 16 '24 | Sell | $25.74 | 1,750 | $45,045.00 | 1,737 | SEC Form 4 |
| Bizily Scott | FDMT | Chief Legal Officer | Apr 1 '24 | Sell | $31.78 | 8,153 | $259,102.34 | 1,737 | SEC Form 4 |
| Bizily Scott | FDMT | Chief Legal Officer | Mar 27 '24 | Sell | $35.04 | 5,833 | $204,410.49 | 1,737 | SEC Form 4 |
| Bizily Scott | FDMT | Chief Legal Officer | Mar 18 '24 | Sell | $31.27 | 1,750 | $54,722.50 | 1,737 | SEC Form 4 |
| Bizily Scott | FDMT | Chief Legal Officer | Feb 27 '24 | Sell | $30.00 | 1,909 | $57,270.00 | 1,737 | SEC Form 4 |
| Bizily Scott | FDMT | Chief Legal Officer | Feb 16 '24 | Sell | $27.67 | 1,750 | $48,422.50 | 1,737 | SEC Form 4 |
| Bizily Scott | FDMT | Chief Legal Officer | Feb 8 '24 | Sell | $27.50 | 1,332 | $36,630.00 | 1,737 | SEC Form 4 |
| Bizily Scott | FDMT | Chief Legal Officer | Feb 8 '24 | Sell | $27.50 | 2,916 | $80,190.00 | 1,737 | SEC Form 4 |
| Bizily Scott | FDMT | Chief Legal Officer | Feb 8 '24 | Sell | $27.50 | 1,996 | $54,890.00 | 1,737 | SEC Form 4 |
| Kirn David | FDMT | Chief Executive Officer | Feb 8 '24 | Sell | $27.13 | 92,001 | $2,495,821.53 | 1,059,153 | SEC Form 4 |
| Kim Robert Young | FDMT | Chief Medical Officer | Feb 5 '24 | Sell | $30.05 | 12,000 | $360,600.00 | 1,595 | SEC Form 4 |
| Kim Robert Young | FDMT | Chief Medical Officer | Feb 5 '24 | Sell | $30.05 | 6,000 | $180,300.00 | 1,595 | SEC Form 4 |
| Kim Robert Young | FDMT | Chief Medical Officer | Feb 5 '24 | Sell | $30.05 | 6,000 | $180,300.00 | 1,595 | SEC Form 4 |
| Kim Robert Young | FDMT | Chief Medical Officer | Feb 5 '24 | Sell | $30.05 | 552 | $16,587.60 | 1,043 | SEC Form 4 |
| Kirn David | FDMT | Chief Executive Officer | Jan 23 '24 | Sell | $18.41 | 5,696 | $104,851.40 | 1,151,154 | SEC Form 4 |
| Kirn David | FDMT | Chief Executive Officer | Dec 15 '23 | Sell | $17.27 | 28,632 | $494,431.69 | 1,230,521 | SEC Form 4 |
| Kirn David | FDMT | Chief Executive Officer | Dec 15 '23 | Sell | $18.13 | 4,702 | $85,242.56 | 1,225,819 | SEC Form 4 |
| Kirn David | FDMT | Chief Executive Officer | Dec 15 '23 | Sell | $20.31 | 40,732 | $827,201.75 | 1,185,087 | SEC Form 4 |
| Kirn David | FDMT | Chief Executive Officer | Dec 15 '23 | Sell | $19.56 | 28,104 | $549,804.17 | 1,156,983 | SEC Form 4 |
Latest 4D Molecular Therapeutics Inc. News
FDMT Breaking Stock News: Dive into FDMT Ticker-Specific Updates for Smart Investing
MT Newswires
8 days ago
BMO Capital Cuts 4D Molecular Therapeutics Price Target to $40 From $63, Maintains Outperform Rating
MT Newswires
9 days ago
Sector Update: Health Care Stocks Lean Lower Premarket Wednesday
MT Newswires
9 days ago
Sector Update: Health Care
MT Newswires
10 days ago
4D Molecular Therapeutics' Phase 2 Trial Shows 4D-150 Therapy Effective in Treating Wet Age-Related Macular Degeneration
GlobeNewswire
10 days ago
4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity
MT Newswires
14 days ago
4d Molecular Therapeutics Insider Sold Shares Worth $290,598, According to a Recent SEC Filing
Zacks
14 days ago
4D Molecular Therapeutics (FDMT) Moves 11.1% Higher: Will This Strength Last?
Insider Monkey
18 days ago
4D Molecular Therapeutics, Inc. (FDMT): Why Are Analysts Bullish On This Shorted Stock?
Compare FDMT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FDMT 4D Molecular Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.